
Salma K Jabbour
Ki Hyeong Lee
Nikolaj Frost
Valeriy Breder
Dariusz M Kowalski

See next page for additional authors

Follow this and additional works at: https://researchrepository.parkviewhealth.org/oncol

Part of the Oncology Commons
Authors
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
The Phase 2 KEYNOTE-799 Nonrandomized Trial

Salma K. Jabbour, MD; Ki Hyeong Lee, MD, PhD; Nikolai Frost, MD; Valeriy Breder, MD, PhD; Dariusz M. Kowalski, MD, PhD; Theodore Pollock, DO; Evgeny Levchenko, MD, PhD; Noemi Reguart, MD, PhD; Alex Martinez-Marti, MD; Baerin Houghton, MBBS, BSc, MM; Jean-Baptiste Paoli, MD; Sufia Safina, MD; Keunchil Park, MD; Takefumi Komiya, MD; Amy Sanford, MD; Vishal Boolell, BSc, MBBS; Hong Liu, MD; Ayman Samkari, MD; Steven M. Keller, MD; Martin Reck, MD

IMPORTANCE Administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) may provide treatment benefit to patients with locally advanced, stage III non–small cell lung cancer (NSCLC).

OBJECTIVE To evaluate treatment outcomes and safety of pembrolizumab plus cCRT in stage III NSCLC.

DESIGN, SETTING, AND PARTICIPANTS The phase 2, nonrandomized, 2-cohort, open-label KEYNOTE-799 study enrolled patients between November 5, 2018, and July 31, 2020, from 52 academic facilities and community-based institutions across 10 countries. As of October 28, 2020, median (range) follow-up was 18.5 (13.6-23.8) months in cohort A and 13.7 (2.9-23.5) months in cohort B. Of 301 patients screened, 216 eligible patients with previously untreated, unresectable, and pathologically/radiologically confirmed stage IIIA/IIIB/IIIC NSCLC with measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) were enrolled.

INTERVENTIONS Patients in cohort A (squamous/nonsquamous) received 1 cycle (3 weeks) of carboplatin (area under the curve [AUC] 6 mg/mL/min), paclitaxel (200 mg/m²), and pembrolizumab (200 mg), followed by carboplatin (AUC 2 mg/mL/min) and paclitaxel (45 mg/m²) once weekly for 6 weeks and 2 cycles of pembrolizumab plus standard thoracic radiotherapy. Patients in cohort B (nonsquamous) received 3 cycles of cisplatin (75 mg/m²), pemetrexed (500 mg/m²), and pembrolizumab (200 mg) every 3 weeks and thoracic radiotherapy in cycles 2 and 3. Patients received 14 additional cycles of pembrolizumab.

MAIN OUTCOMES AND MEASURES Coprimary end points were objective response rate per RECIST v1.1 by blinded independent central review and incidence of grade 3 to 5 pneumonitis.

RESULTS A total of 112 patients received treatment in cohort A (76 men [67.9%]; median [range] age, 66.0 [46-90] years; 66 patients [58.9%] with programmed cell death ligand 1 [PD-L1] tumor proportion score ≥1%) and 102 patients received treatment in cohort B (62 men [60.8%]; median [range] age, 64.0 [35-81] years; 40 patients [39.2%] with PD-L1 tumor proportion score ≥1%). Objective response rate was 70.5% (79 of 112; 95% CI, 61.2%-78.8%) in cohort A and 70.6% (72 of 102; 95% CI, 60.7%-79.2%) in cohort B. Median duration of response was not reached, but 79.7% and 75.6%, respectively, had response duration of 12 months or longer. Grade 3 or higher pneumonitis occurred in 9 of 112 patients (8.0%) in cohort A and 7 of 102 (6.9%) in cohort B. Grade 3 to 5 treatment-related adverse events occurred in 72 of 112 (64.3%) and 51 of 102 (50.0%) patients, respectively.

CONCLUSIONS AND RELEVANCE The findings of this phase 2, nonrandomized, 2-cohort study suggest promising antitumor activity of pembrolizumab plus cCRT and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC.
A

approximately 25% of patients diagnosed with non-

cell lung cancer (NSCLC) present with tumor

stages IIIA to IIIC, a majority of which are unresectable.1

Until recently, platinum-doublet chemotherapy concurrent

with radiotherapy (cCRT) was the standard of care2 with re-

ported 5-year survival rates between 16% and 32%.3,4 In 2018,

durvalumab, a monoclonal antibody against programmed cell
death ligand 1 (PD-L1), was approved by the European Medi-
cines Agency for patients with locally advanced, unresect-
able NSCLC with PD-L1 expression on 1% or greater of tumor

cells whose disease did not progress after cCRT5 and by the US

Food and Drug Administration irrespective of PD-L1 expres-
sion.6-8

However, approximately 22% to 30% of patients with un-

resectable stage III NSCLC who begin cCRT experience dis-

ease progression (PD) or toxic effects and are unable to com-

plete the prescribed cCRT. This substantial patient population
does not meet the criteria for durvalumab as consolidative

therapy.9,10 We postulated that administration of concurrent

anti–programmed cell death1 (PD-1) therapy and cCRT as ini-
tial therapy may provide treatment benefit to a greater pro-

portion of patients with locally advanced, unresectable, stage

III NSCLC.

Pembrolizumab, a highly selective humanized monoclo-
nal anti–PD-1 antibody, inhibits the interaction between PD-1

and its ligands PD-L1 and PD-L2, promoting T-cell–mediated

antitumor activity.11 Pembrolizumab has demonstrated long-
term survival and durable clinical benefit as first-line treat-

ment in patients with advanced or metastatic NSCLC with

PD-L1 tumor proportion score (TPS) 1% or greater as monotherapy12,13 and in combination with chemotherapy in

patients with advanced or metastatic NSCLC irrespective of

PD-L1 expression.14-16 The phase 2 KEYNOTE-799 study

(NCT03631784) was designed as a 2-cohort nonrandomized,

international study to assess treatment outcomes following

concomitant pembrolizumab plus cCRT in patients with

unresectable, locally advanced stage III NSCLC.

**Methods**

**Study Design and Patients**

KEYNOTE-799 is a nonrandomized, global, open-label phase

2 study that was conducted at 52 academic facilities and com-

munity-based institutions across 10 countries (the US, Aus-

tralia, France, Germany, Republic of Korea, New Zealand, Pol-

land, Russia, Spain, and the UK) in accordance with Good

Clinical Practice guidelines and the Declaration of Helsinki.
The study protocol and amendments were approved by institu-
tional review boards or independent ethics committees at each

study site. All patients provided written informed consent be-

fore undergoing any protocol-specific procedure.

Eligibility requirements included age 18 years and older;

previously untreated, unresectable, pathologically or radio-

logically confirmed stage IIIA, IIIB, or IIIC NSCLC per Ameri-
can Joint Committee on Cancer version 8 staging17; measur-
able disease per Response Evaluation Criteria in Solid Tumors,

version 1.1 (RECIST v1.1) per investigator review; Eastern

Cooperative Oncology Group performance status of 0 or 1; ad-

equate organ function; forced expiratory volume in first sec-
don (FEV1) greater than 50% of predicted normal volume and
carbon monoxide lung diffusing capacity greater than 40% of

predicted normal value; provision of a cytologic or histologic
tumor tissue sample; and no evidence of metastatic disease

by whole-body positron emission tomography, computed tomo-
graphy scan, diagnostic-quality computed tomography scan,

and brain imaging. Patients were excluded if they had any of

the following: prior radiotherapy to the thorax (including

radiotherapy for esophageal or breast cancer), radiation treat-

ment plans that were likely to encompass a volume of

whole lung receiving more than 20 Gy in greater than 31% of

total lung volume, prior therapy with an anti–PD-(L)1 antibo-
dy, a diagnosis of immunodeficiency or were receiving

chronic systemic steroid therapy, an active autoimmune
disease requiring systemic treatment, a history of noninfect-
ous pneumonitis or interstitial lung disease that required the

use of steroids, or an active infection requiring systemic

therapy. Full eligibility criteria are described in the protocol

in Supplement 1.

**Treatment**

Patients with nonsquamous NSCLC were eligible for either co-

hort and were allocated to treatment per investigator assign-
mant; patients with squamous NSCLC were eligible for co-

hort A only. Patients in cohort A received 1 cycle of carboplatin

(area under the concentration curve [AUC] 6 mg/mL/min), pa-

citaxel (200 mg/m²), and pembrolizumab (200 mg), on day 1

of a 3-week cycle, all administered intravenously. After 3 weeks,

patients received carboplatin (AUC 2 mg/mL/min) and pacli-
taxel (45 mg/m²), weekly for 6 weeks and 2 cycles of pembrol-

izumab (200 mg) every 3 weeks plus thoracic radiotherapy.

Patients in cohort B had nonsquamous NSCLC and received 3

cycles of cisplatin (75 mg/m²) and pemetrexed (500 mg/m²) plus
goembralizumab (200 mg) on day 1 of each 3-week cycle plus

standard thoracic radiotherapy in cycles 2 and 3. Tho-

racic radiotherapy was administered 5 days per week in once-
daily fractions of 2 Gy per fraction to a target dose of 60 Gy in

30 fractions using standardized radiotherapy techniques on

linear accelerators operating at a beam energy of 6 megavolts

Key Points

**Question** Is administration of pembrolizumab plus concurrent

chemoradiation therapy (cCRT) effective and safe in patients with

locally advanced, stage III non–small cell lung cancer (NSCLC)?

**Findings** In this nonrandomized 2-cohort trial, pembrolizumab

plus cCRT demonstrated objective response rates of 70.5% in

cohort A (n = 112; squamous/non-squamous) and 70.6% in cohort

B (n = 102; nonsquamous). The incidence of grade 3 or higher

pneumonitis was 8.0% in cohort A and 6.9% in cohort B.

**Meaning** The findings of this 2-cohort trial suggest robust

antitumor activity of pembrolizumab plus cCRT with manageable

safety that may represent a promising therapy in patients with

previously untreated, locally advanced, stage III NSCLC.
or higher. Additional thoracic radiotherapy details are provided in the eMethods in Supplement 2 and the study protocol in Supplement 1. After cCRT, all patients received an additional 14 cycles of pembrolizumab (200 mg) every 3 weeks, for a total of 17 cycles (approximately 1 year) or until documented PD, unacceptable adverse events (AEs), intercurrent illness, investigator’s decision, or patient withdrawal of consent. Patients who experienced PD or started a new anticancer therapy were followed up for survival status every 12 weeks until death, withdrawal of consent, or the end of the study.

**Assessments**

Tumor imaging occurred at baseline, then every 9 weeks until week 54, every 12 weeks until week 150, and every 24 weeks thereafter. Response was assessed by blinded independent central review (BICR) per RECIST v1.1 (allowing a maximum of 10 target lesions in total and 5 per organ). In addition, response assessment included local progression (ie, growth of existing lesions or appearance of lesions within the same lung lobe as primary lesion) and metastatic disease (appearance of lesions elsewhere).

Tumor tissue samples (formalin-fixed, paraffin-embedded tissue blocks preferred) were obtained via core, incisional, or excisional biopsy before treatment allocation to establish the diagnosis of NSCLC and to determine the PD-L1 TPS (percentage of tumor cells with membranous PD-L1 staining). Expression of PD-L1 was assessed centrally using the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies). Cytologic specimens were not analyzed for PD-L1 expression but were used to confirm the diagnosis of NSCLC.

**End Points**

The primary end points were objective response rate (ORR) assessed by BICR per RECIST v1.1 and the percentage of patients who developed grade 3 or higher pneumonitis according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Secondary end points included overall survival (OS), progression-free survival (PFS) by BICR per RECIST v1.1, and safety.

**Statistical Analysis**

Treatment outcomes and toxicity were assessed in all patients who received at least 1 dose of study treatment. Binomial sequential testing was conducted to evaluate grade 3 or higher pneumonitis and ORR. With approximately 108 patients in each cohort, the study provided 83% power to demonstrate that the percentage of patients with grade 3 or higher pneumonitis was less than 10% if the true rate of grade 3 or higher pneumonitis was 3% at an overall 1-sided 5% α level. The study also provided 84% power to demonstrate that the ORR exceeds 35% at an overall 1-sided 5% level if the true ORR was 50%. The Clopper-Pearson method was used to estimate the CIs for ORR and the percentage of patients with grade 3 or higher pneumonitis. Patients in the as-treated population with missing ORR data were counted as nonresponders. The Kaplan-Meier method was used to estimate PFS, OS, and duration of response (DOR). Statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc). Treatment outcomes and safety data were periodically reviewed by an external data monitoring committee. Continuous interim analyses using binomial sequential testing were performed to allow either treatment cohort to stop if the percentage of participants with grade 3 or higher pneumonitis was unacceptable high, stop for futility if the ORR is low, or stop to enable rapid progression to phase 3 if criteria were met. The first interim analysis took place when 36 or more patients had at least 15 weeks of follow-up in either cohort.

**Results**

**Patients**

Between November 5, 2018, and July 31, 2020, 216 patients were enrolled in KEYNOTE-799, of whom 112 were allocated to cohort A and 104 to cohort B. All 112 patients in cohort A (76 men [67.9%]; median [range] age, 66.0 [46-90] years) and 102 patients in cohort B (62 men [60.8%]; median [range] age, 64.0 [35-81] years) received pembrolizumab in cohort A, while 30 patients (29.4%) were receiving pembrolizumab in cohort B. Between November 5, 2018, and July 31, 2020, 216 patients were enrolled in KEYNOTE-799, of whom 112 were allocated to cohort A and 104 to cohort B. All 112 patients in cohort A (76 men [67.9%]; median [range] age, 66.0 [46-90] years) and 102 patients in cohort B (62 men [60.8%]; median [range] age, 64.0 [35-81] years) received pembrolizumab in cohort A, while 30 patients (29.4%) were receiving pembrolizumab in cohort B.

**Tumor Imaging**

Tumor imaging occurred at baseline, then every 9 weeks until week 54, every 12 weeks until week 150, and every 24 weeks thereafter. Response was assessed by blinded independent central review (BICR) per RECIST v1.1 (allowing a maximum of 10 target lesions in total and 5 per organ). In addition, response assessment included local progression (ie, growth of existing lesions or appearance of lesions within the same lung lobe as primary lesion) and metastatic disease (appearance of lesions elsewhere).

**Statistical Analysis**

Treatment outcomes and toxicity were assessed in all patients who received at least 1 dose of study treatment. Binomial sequential testing was conducted to evaluate grade 3 or higher pneumonitis and ORR. With approximately 108 patients in each cohort, the study provided 83% power to demonstrate that the percentage of patients with grade 3 or higher pneumonitis was less than 10% if the true rate of grade 3 or higher pneumonitis was 3% at an overall 1-sided 5% α level. The study also provided 84% power to demonstrate that the ORR exceeds 35% at an overall 1-sided 5% level if the true ORR was 50%. The Clopper-Pearson method was used to estimate the CIs for ORR and the percentage of patients with grade 3 or higher pneumonitis. Patients in the as-treated population with missing ORR data were counted as nonresponders. The Kaplan-Meier method was used to estimate PFS, OS, and duration of response (DOR). Statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc). Treatment outcomes and safety data were periodically reviewed by an external data monitoring committee. Continuous interim analyses using binomial sequential testing were performed to allow either treatment cohort to stop if the percentage of participants with grade 3 or higher pneumonitis was unacceptable high, stop for futility if the ORR is low, or stop to enable rapid progression to phase 3 if criteria were met. The first interim analysis took place when 36 or more patients had at least 15 weeks of follow-up in either cohort.
were 4 (3.6%) fatal treatment-related AEs in cohort A, all due to pneumonitis, and 1 in cohort B owing to interstitial lung disease. All fatal AEs were attributed by the investigator to treatment with pembrolizumab, with the exception of 1 case of pneumonitis that was attributed to both pembrolizumab and radiotherapy.

Safety

Treatment-related AEs, as determined by the investigator, were reported in 105 patients (93.8%) in cohort A and 99 (97.1%) in cohort B. Grade 3 to 5 AEs occurred in 72 patients (64.3%) in cohort A and 51 (50.0%) in cohort B. The most common grade 3 or higher treatment-related AE was neutropenia in both cohort A (16.1%) and cohort B (9.8%). There were 4 (3.6%) fatal treatment-related AEs in cohort A, all owing to pneumonitis, and 1 in cohort B owing to interstitial lung disease. All fatal AEs were attributed by the investigator to treatment with pembrolizumab, with the exception of 1 case of pneumonitis that was attributed to both pembrolizumab and radiotherapy.

Discontinuation of any study treatment because of a treatment-related AE occurred in 38 patients (33.9%) in cohort A and 19 (18.6%) in cohort B (Table 3). Pneumonitis was the most frequent treatment-related AE leading to discontinuation in both cohort A (11.6%) and cohort B (5.9%). Immune-mediated AEs occurred in 51 patients (45.5%) in cohort A and 41 (40.2%) in cohort B, and infusion reactions occurred in 10 patients (8.9%) and 2 patients (2.0%), respectively. Grade 3 to 5 immune-mediated AEs occurred in 16 patients (14.3%) in cohort A and 9 (8.8%) in cohort B; 4 patients (3.6%) in cohort A and 1 (1.0%) in cohort B died.

### Table 2. Objective Response in All Patients as Treated

<table>
<thead>
<tr>
<th>Response</th>
<th>Cohort A (n = 112)</th>
<th>Cohort B (n = 102)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR, No. (%)[95% CI]</td>
<td>79 (70.5) [61.2 to 78.8]</td>
<td>72 (70.6) [60.7 to 79.2]</td>
</tr>
<tr>
<td>Best overall response, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete response</td>
<td>4 (3.6)</td>
<td>5 (4.9)</td>
</tr>
<tr>
<td>Partial response</td>
<td>75 (67.0)</td>
<td>67 (65.7)</td>
</tr>
<tr>
<td>Stable disease</td>
<td>20 (17.9)</td>
<td>23 (22.5)</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>1 (0.9)</td>
<td>0</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>2 (1.8)</td>
<td>0</td>
</tr>
<tr>
<td>No assessment</td>
<td>10 (8.9)</td>
<td>7 (6.9)</td>
</tr>
<tr>
<td>Time to response, median (range), mo</td>
<td>2.1 (1.1 to 13.4)</td>
<td>2.1 (1.3 to 10.1)</td>
</tr>
<tr>
<td>Duration of response, median (range), mo</td>
<td>NR (1.7+ to 19.7+)</td>
<td>NR (1.8+ to 21.4+)</td>
</tr>
<tr>
<td>Patients with response ≥12 mo, %</td>
<td>79.7</td>
<td>75.6</td>
</tr>
</tbody>
</table>

Abbreviations: NR, not reached; ORR, objective response rate.

* Includes 11 patients in cohort A and 6 patients in cohort B who did not receive all of the planned radiotherapy treatment. This was due to inability to provide treatment per protocol (n = 6; of whom 5 discontinued on day 1, and 1 discontinued on day 22), physician decision (n = 3; discontinued treatment on day 1), patient withdrawal (n = 1; discontinued treatment on day 1), and adverse event (n = 1; discontinued treatment on day 1), and protocol violation (n = 2); discontinued treatment on day 1 and day 42, respectively) in cohort B.

* Includes patients with confirmed complete or partial response.

* Postbaseline assessment(s) was available but was not evaluable or complete response/partial response/stable disease less than 6 weeks from the date of first dose.

* No postbaseline assessment available for response evaluation.

* Includes patients with clinical progression and progressive disease.

* From Kaplan-Meier method for censored data.

* Includes 11 patients in cohort A and 6 patients in cohort B who did not receive all of the planned radiotherapy treatment. This was due to inability to provide treatment per protocol (n = 6; of whom 5 discontinued on day 1, and 1 discontinued on day 22), physician decision (n = 3; discontinued treatment on day 1), patient withdrawal (n = 1; discontinued treatment on day 1), and adverse event (n = 1; discontinued treatment on day 1), and protocol violation (n = 2); discontinued treatment on day 1 and day 42, respectively) in cohort B.

* Includes patients with clinical progression and progressive disease.

* Postbaseline assessment(s) was available but was not evaluable or complete response/partial response/stable disease less than 6 weeks from the date of first dose.

* No postbaseline assessment available for response evaluation.

* Includes patients with confirmed complete or partial response.

* From Kaplan-Meier method for censored data.

Safety

Treatment-related AEs, as determined by the investigator, were reported in 105 patients (93.8%) in cohort A and 99 (97.1%) in cohort B. Grade 3 to 5 AEs occurred in 72 patients (64.3%) in cohort A and 51 (50.0%) in cohort B. The most common grade 3 or higher treatment-related AE was neutropenia in both cohort A (16.1%) and cohort B (9.8%). There were 4 (3.6%) fatal treatment-related AEs in cohort A, all due to pneumonitis, and 1 in cohort B owing to interstitial lung disease. All fatal AEs were attributed by the investigator to treatment with pembrolizumab, with the exception of 1 case of pneumonitis that was attributed to both pembrolizumab and radiotherapy.

Discontinuation of any study treatment because of a treatment-related AE occurred in 38 patients (33.9%) in cohort A and 19 (18.6%) in cohort B (Table 3). Pneumonitis was the most frequent treatment-related AE leading to discontinuation in both cohort A (11.6%) and cohort B (5.9%). Immune-mediated AEs occurred in 51 patients (45.5%) in cohort A and 41 (40.2%) in cohort B, and infusion reactions occurred in 10 patients (8.9%) and 2 patients (2.0%), respectively. Grade 3 to 5 immune-mediated AEs occurred in 16 patients (14.3%) in cohort A and 9 (8.8%) in cohort B; 4 patients (3.6%) in cohort A and 1 (1.0%) in cohort B died.

### Table 2. Objective Response in All Patients as Treated

<table>
<thead>
<tr>
<th>Response</th>
<th>Cohort A (n = 112)</th>
<th>Cohort B (n = 102)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR, No. (%)[95% CI]</td>
<td>79 (70.5) [61.2 to 78.8]</td>
<td>72 (70.6) [60.7 to 79.2]</td>
</tr>
<tr>
<td>Best overall response, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete response</td>
<td>4 (3.6)</td>
<td>5 (4.9)</td>
</tr>
<tr>
<td>Partial response</td>
<td>75 (67.0)</td>
<td>67 (65.7)</td>
</tr>
<tr>
<td>Stable disease</td>
<td>20 (17.9)</td>
<td>23 (22.5)</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>1 (0.9)</td>
<td>0</td>
</tr>
<tr>
<td>Not evaluable</td>
<td>2 (1.8)</td>
<td>0</td>
</tr>
<tr>
<td>No assessment</td>
<td>10 (8.9)</td>
<td>7 (6.9)</td>
</tr>
<tr>
<td>Time to response, median (range), mo</td>
<td>2.1 (1.1 to 13.4)</td>
<td>2.1 (1.3 to 10.1)</td>
</tr>
<tr>
<td>Duration of response, median (range), mo</td>
<td>NR (1.7+ to 19.7+)</td>
<td>NR (1.8+ to 21.4+)</td>
</tr>
<tr>
<td>Patients with response ≥12 mo, %</td>
<td>79.7</td>
<td>75.6</td>
</tr>
</tbody>
</table>

Abbreviations: NR, not reached; ORR, objective response rate.

* Includes 11 patients in cohort A and 6 patients in cohort B who did not receive all of the planned radiotherapy treatment. This was due to inability to provide treatment per protocol (n = 6; of whom 5 discontinued on day 1, and 1 discontinued on day 22), physician decision (n = 3; discontinued treatment on day 1), patient withdrawal (n = 1; discontinued treatment on day 1), and adverse event (n = 1; discontinued treatment on day 1), and protocol violation (n = 2); discontinued treatment on day 1 and day 42, respectively) in cohort B.

* Includes patients with confirmed complete or partial response.

* Postbaseline assessment(s) was available but was not evaluable or complete response/partial response/stable disease less than 6 weeks from the date of first dose.

* No postbaseline assessment available for response evaluation.

* Includes patients with clinical progression and progressive disease.

* From Kaplan-Meier method for censored data.
owing to pneumonitis. The most common grade 3 to 5 immune-mediated AE was pneumonitis (cohort A, 7 [6.3%]; cohort B, 6 [5.9%]). Grade 3 infusion reactions occurred in 3 patients (2.7%) in cohort A and none in cohort B; there were no grade 4 or 5 infusion reactions in either cohort (Table 3).

Grade 3 or higher pneumonitis (coprimary end point), including radiation pneumonitis, occurred in 9 of 112 patients (8.0%; 95% CI, 3.7%-14.7%) in cohort A and 7 of 102 patients (6.9%; 95%, 2.8%-13.6%) in cohort B (eTable 2 in Supplement 2). Median (range) time to onset of first pneumonitis was 4.3 (1.4-10.4) months in cohort A and 4.4 (0.1-12.3) months in cohort B, and median (range) episode duration was 4.4 (0.1+ to 20.3+) months and 4.0 (0.3-13.6+) months, respectively (where “+” indicates the AE episode had not recovered or resolved by the time of data cutoff or death).

Discussion
To our knowledge, KEYNOTE-799 is the largest trial to date of concurrent anti–PD-(L)1 therapy plus cCRT in patients with previously untreated, locally advanced, stage III NSCLC. In this study, pembrolizumab plus cCRT demonstrated robust antitumor activity with a manageable safety profile.

The ORR was approximately 70% in each cohort of KEYNOTE-799, and objective response was estimated to last at least 12 months in more than 75% of patients in each cohort. A phase 1 study of concomitant pembrolizumab plus cCRT in patients with stage IIIA/IIIB NSCLC produced similar results (ORR, 89% in 17 of 19 evaluable patients).20 Results from KEYNOTE-799 were also similar to those observed in the phase 2 European Thoracic Oncology Platform (ETOP) NICOLAS study of 79 patients with locally advanced stage IIIA/IIIB NSCLC treated with concomitant nivolumab (an anti–PD-1 antibody) plus cCRT with a reported ORR of 73.4% and median DOR of 11.0 months.21 Although cross-trial comparisons are challenging given differences in radiotherapy dosing and specific chemotherapy regimens, historically, ORRs with cCRT (platinum-pemetrexed or platinum-taxane plus thoracic radiotherapy) with or without consolidation chemotherapy have been between 35.9% and 54.5%.22-24

Responses in KEYNOTE-799 were observed irrespective of disease stage, tumor histologic type, and PD-L1 expression. Pembrolizumab monotherapy also demonstrated antitumor activity in patients with advanced or metastatic NSCLC with PD-L1 TPS less than 1% in the phase 1 KEYNOTE-001 study,25 albeit less than that observed in patients with PD-L1 TPS 1% or greater. In the stage III setting, no association of PFS by PD-L1 expression was observed in a limited number of patients in the phase 1 study of pembrolizumab plus cCRT,20 and no difference in PFS or OS was observed in a phase 2 study of consolidation pembrolizumab following cCRT.26 In the PACIFIC study of consolidation durvalumab after cCRT, benefits were more pronounced in the intention-to-treat population (ORR, 30.0% vs 17.8% [for durvalumab vs placebo]; PFS hazard ratio [HR], 0.51; OS HR, 0.68) in comparison to ad hoc exploratory analyses in patients with PD-L1-negative disease (PD-L1 < 1%: ORR, 24.7% vs 21.6%; PFS HR, 0.73; OS HR, 1.14; PD-L1 ≥ 1%: ORR, 31.0% vs 16.5%; PFS HR, 0.46; OS HR, 0.59).27 While different PD-L1 testing platforms were used in KEYNOTE-799 and PACIFIC, unlike PACIFIC, results from KEYNOTE-799 suggest antitumor activity with pembrolizumab in patients with both PD-L1-positive and PD-L1-negative NSCLC. This is similar to the findings from phase 2 and 3 trials of pembrolizumab plus chemotherapy in patients with advanced NSCLC with PD-L1 TPS less than 1%.28

After more than 1 year of follow-up in KEYNOTE-799, median OS and PFS were not reached in either cohort. These
findings are encouraging but not unanticipated, given the observed high ORR and prolonged DOR. Furthermore, the survival outcomes in KEYNOTE-799 are promising compared with other studies investigating anti–PD-(L)1 therapy plus cCRT with similar or longer follow-up durations, including the ETOPI NICOLAS trial of nivolumab plus cCRT (median follow-up time of 21 months or longer [for OS follow-up]; median PFS, 12.7 months; median OS, 38.8 months; 1-year PFS rate, 53.7%; 1-year OS rate, 75.6%), 21,22 the DETERRED study of atezolizumab plus cCRT (median follow-up, 15.3 months; median OS, not reached; median PFS, 13.2 months), 23 and in comparison to a study evaluating cCRT alone in patients with stage IIIA/IIIB NSCLC (median follow-up, 21.3 months; median PFS, 10.7 months; median OS, 24.0 months; 1-year PFS rate, 46.3%). 20

Pneumonitis and radiation pneumonitis are common AEs associated with anti–PD-(L)1 administration and cCRT, 20,21 and concurrent administration of both therapies might result in greater pulmonary toxicity than the sum of toxicity with each treatment individually. The incidence of grade 3 or higher pneumonitis was less than 10% in each cohort in KEYNOTE-799; 4 patients in cohort A and 1 in cohort B died from pneumonitis. These findings are consistent with other studies of anti–PD-(L)1 therapies in combination with cCRT, including pembrolizumab concurrent with cCRT (overall, grade 3-5 pneumonitis in 2 of 21 patients [10%]), 20 pembrolizumab consolidation after cCRT (grade 3-5 pneumonitis in 6 of 93 patients [6%]), 26 nivolumab concurrent with cCRT (grade 3-5 pneumonitis in 9 of 77 patients [12%]), 23 and atezolizumab concurrent with cCRT (grade 3-5 pneumonitis in 1 of 30 patients [3%] in part 2 of the DETERRED trial). 21 In the PACIFIC trial, 20 of 475 patients (4%) had grade 3 or 5 pneumonitis; however, as part of the eligibility criteria for the PACIFIC study, patients with grade 2 or higher pneumonitis from previous chemoradiotherapy were excluded from receiving consolidation durvalumab therapy. 7 Together, the incidence of grade 3 or higher pneumonitis observed in KEYNOTE-799 was consistent with established toxicity profiles of cCRT for stage III NSCLC, 12 and the overall safety profile was in line with the AEs observed with pembrolizumab monotherapy or in combination with chemotherapy in first-line advanced NSCLC. 12,33,34

Limitations
KEYNOTE-799 had certain limitations related to the design as a nonrandomized phase 2 trial. Formal comparisons between the 2 study cohorts or with standard-of-care regimens were not intended. Additionally, follow-up duration in cohort B is limited because many patients are still receiving study therapy. Longer follow-up will provide further information on the outcomes of OS and PFS following study treatment. Further insight is expected from the ongoing phase 3 KEYLYNK-012 study (NCT04380636) evaluating pembrolizumab plus cCRT followed by pembrolizumab with or without the poly-(adenosine diphosphate-ribose) polymerase inhibitor olaparib vs cCRT followed by durvalumab in patients with unresectable, locally advanced, stage III NSCLC; the phase 3 PACIFIC-2 study (durvalumab plus cCRT; NCT03519971); the phase 3 ECOG-ACRIN EA5181 study (cCRT with or without durvalumab followed by consolidation durvalumab; NCT04092283); and the phase 3 NRG-LU004 study (durvalumab combined with accelerated hypofractionated or conventionally fractionated radiotherapy in PD-L1–high stage II-III NSCLC; NCT03801902).

Conclusions
In the nonrandomized KEYNOTE-799 trial, concomitant pembrolizumab plus cCRT demonstrated robust antitumor
activity, regardless of tumor histologic type and PD-L1 TPS, with manageable toxicity. This treatment regimen represents a promising therapy in patients with previously untreated, locally advanced, stage III NSCLC.

**Table 3. Adverse Events Summary**

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>No. (%)</th>
<th>Cohort A (n = 112)</th>
<th>Cohort B (n = 102)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment-related adverse event&lt;sup&gt;a&lt;/sup&gt;</td>
<td>105 (93.8)</td>
<td>99 (97.1)</td>
<td></td>
</tr>
<tr>
<td>Grade 3-5</td>
<td>72 (64.3)</td>
<td>51 (50.0)</td>
<td></td>
</tr>
<tr>
<td>Led to discontinuation of any treatment</td>
<td>38 (33.9)</td>
<td>19 (18.6)</td>
<td></td>
</tr>
<tr>
<td>Led to death</td>
<td>4 (3.6)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1 (1.0)&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Occurring in ≥15% of patients in either cohort</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>35 (31.3)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>38 (33.9)</td>
<td>12 (10.7)</td>
<td></td>
</tr>
<tr>
<td>Asthenia</td>
<td>15 (13.4)</td>
<td>1 (0.9)</td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>17 (15.2)</td>
<td>2 (1.8)</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>16 (14.3)</td>
<td>4 (3.6)</td>
<td></td>
</tr>
<tr>
<td>Dysphagia</td>
<td>22 (19.6)</td>
<td>1 (0.9)</td>
<td></td>
</tr>
<tr>
<td>Esophagitis</td>
<td>19 (17.0)</td>
<td>3 (2.7)</td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>32 (28.6)</td>
<td>3 (2.7)</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>23 (20.5)</td>
<td>2 (1.8)</td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>32 (28.6)</td>
<td>18 (16.1)</td>
<td></td>
</tr>
<tr>
<td>Neutrophil count decreased</td>
<td>19 (17.0)</td>
<td>10 (8.9)</td>
<td></td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>22 (19.6)</td>
<td>7 (6.3)</td>
<td></td>
</tr>
<tr>
<td>Radiation pneumonitis</td>
<td>20 (17.9)</td>
<td>2 (1.8)</td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>18 (16.1)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>18 (16.1)</td>
<td>4 (3.6)</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>8 (7.1)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Immune-mediated adverse events and infusion reactions</td>
<td></td>
<td>58 (51.8)</td>
<td>42 (41.2)</td>
</tr>
<tr>
<td>Overall immune-mediated adverse events and infusion reactions</td>
<td></td>
<td>21 (18.8)</td>
<td>11 (10.8)</td>
</tr>
<tr>
<td>Led to discontinuation of any treatment</td>
<td>4 (3.6)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1 (1.0)&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Occurring in any patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colitis</td>
<td>0 (0.0)</td>
<td>3 (2.9)</td>
<td></td>
</tr>
<tr>
<td>Encephalitis</td>
<td>0 (0.0)</td>
<td>1 (1.0)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis</td>
<td>2 (1.8)</td>
<td>2 (2.0)</td>
<td></td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>10 (8.9)</td>
<td>2 (1.8)</td>
<td></td>
</tr>
<tr>
<td>Hypophysitis</td>
<td>1 (0.9)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>18 (16.1)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Infusion reactions</td>
<td>18 (16.1)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Myasthenic syndrome</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
<td></td>
</tr>
<tr>
<td>Myocarditis</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
<td></td>
</tr>
<tr>
<td>Myositis</td>
<td>1 (0.9)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>25 (22.3)</td>
<td>7 (6.3)</td>
<td></td>
</tr>
<tr>
<td>Severe skin reactions</td>
<td>4 (3.6)</td>
<td>4 (3.6)</td>
<td></td>
</tr>
<tr>
<td>Thyroiditis</td>
<td>0 (0.0)</td>
<td>2 (2.0)</td>
<td></td>
</tr>
<tr>
<td>Uveitis</td>
<td>1 (0.9)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Determined by investigator to be related to the drug.  
<sup>b</sup> Four patients died from treatment-related pneumonitis.  
<sup>c</sup> One patient died from treatment-related interstitial lung disease.

**ARTICLE INFORMATION**

Accepted for Publication: May 3, 2021.  
Published Online: June 4, 2021. doi:10.1001/jamaoncol.2021.2301  
Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2021 Jabbour SK et al. JAMA Oncology.

**Author Affiliations:** Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick (Jabbour); Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea (Lee); Department of Infectious Diseases and Respiratory Medicine, Chanté-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany (Frost); N.N. Blokhin Russian Cancer Research Center, Moscow, Russia (Breder); The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland (Kowalski); Northeastern Health System, Tahlequah, Oklahoma (Pollock); N.N. Petrov National Medical Research Center of Oncology, St Petersburg, Russia.
(Levchenko); Thoracic Oncology Unit, Department of Medical Oncology, IDIBAPS, Hospital Clinic, Barcelona, Spain (Martinez-Marti); Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain (Martinez-Marti); Mid North Coast Cancer Institute, Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia (Houghton); Radiotherapy, Clinique Clairval, Marseille, France (Paoli); Medical Oncology, Republican Dispensary of Tatarstan Ministry of Healthcare, Kazan, Russia (Safina); Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (Park); Hematology/Oncology, Parkview Cancer Institute, Fort Wayne, Indiana (Koymia); Sanford Health, Sioux Falls, South Dakota (Sanford); Ballarat Health Services, Ballarat, Victoria, Australia (Booelli); Merck & Co, Inc, Kenilworth, New Jersey (Liu, Samkari, Keller); LungClinic, Airway Research Center North, German Center for Lung Research, Grosshadorf, Germany (Reck).”

**Author Contributions:** Dr. Jabbour had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Jabbour, Park, Reck.

**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Jabbour, Martinez-Marti, Park, Samkari.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Liu, Samkari.

**Administrative, technical, or material support:** Lee, Houghton, Koymia, Keller, Reck.

**Supervision:** Jabbour, Lee, Frost, Pollock, Levchenko, Martinez-Marti, Houghton, Paoli, Park, Sanford, Samkari, Keller, Reck.

**Other—patient recruitment:** Reguart.

**Conflict of Interest Disclosures:** Dr. Jabbour reported receiving grants, personal fees, and nonfinancial support from Merck & Co during the conduct of the study; and receiving grants from the National Cancer Institute and grants to institution from Merck & Co outside the submitted work. Dr. Lee reported receiving personal fees for advisory board meetings from Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Pfizer, and Eli Lilly outside the submitted work. Dr. Frost reported receiving personal fees and nonfinancial support from Merck Sharp & Dohme during the conduct of the study; and receiving personal fees from Boehringer Ingelheim, Bristol Myers Squibb, Roche, Pfizer, Takeda, Novartis, and AbbVie, Berlin-Chemie, Sanofi, and Beigene; travel grants from Takeda, AstraZeneca, Bristol Myers Squibb, AbbVie, and Eli Lilly; and nonfinancial support from Bristol Myers Squibb outside the submitted work. Dr. Kowalski reported serving on advisory boards for Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Takeda, and Roche outside the submitted work. Dr. Reguart reported receiving grants from Novartis and Pfizer, personal fees (advisory panels, invited speaker, congress registration) from Merck Sharp & Dohme, Eli Lilly, Roche, Takeda, Novartis, Pfizer, and Janssen, and personal fees (advisory panels, invited speaker) from Bristol Myers Squibb outside the submitted work. Dr. Martinez-Marti reported receiving personal fees and travel expenses from Bristol Myers Squibb, F. Hoffmann-La Roche, Merck Sharp & Dohme, Pfizer, Boehringer Ingelheim, Merck Sharp & Dohme Oncology, and AstraZeneca outside the submitted work. Dr. Houghton reported receiving personal fees (advisory board) from Merck outside the submitted work. Dr. Paoli reported receiving nonfinancial support from Merck Sharp & Dohme during the conduct of the study; and receiving personal fees from Bristol Myers Squibb and AstraZeneca and nonfinancial support from Merck Sharp & Dohme France, Fresenius Kabi France, Ipsen Pharma, Boehringer Ingelheim France, Pierre Fabre Medicament, Elias SAS, Janssen-Cilag, Pfizer SAS, Roche SAS, Isis Médiatrice, Novartis Pharma SAS, Mundipharma, Vifor France SA, Sandoz, Kyowa Kirin, Bristol Myers Squibb, and AstraZeneca outside the submitted work. Dr. Park reported receiving grants (research funding) from Merck Sharp & Dohme outside the submitted work; and serving as an advisor for Merck Sharp & Dohme outside the submitted work. Dr. Sanford reported receiving grants to institution from Merck during the conduct of the study; and receiving grants from Eli Lilly, Novartis, and QuantumLeap Health outside the submitted work. Drs Liu, Samkari, and Keller reported being an employee of Merck. Dr. Reck reported receiving personal fees (honoria for lectures and consultations) from Agena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Mirati, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Samsung Bioepis outside the submitted work. No other disclosures were reported.

**Funding/Support:** Funding for this research was provided by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, New Jersey.

**Role of the Funder/Sponsor:** The sponsor was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Meeting Presentation:** A portion of the results from this analysis was presented virtually at the 2021 American Society of Clinical Oncology Annual Meeting, June 4, 2021.

**Data Sharing Statement:** See Supplement 3.

**Additional Contributions:** Medical writing assistance was provided by Christabel Wilson, MSc, and Shilpa Kamboj, PhD, of ICON plc (North Wales, Pennsylvania). This assistance was funded by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, New Jersey. We thank the patients and their families and caregivers for participating in this study, along with all investigators and site personnel.

**REFERENCES**


